Functional characterization of the mechanisms underlying bradykinin-induced relaxation in the isolated rat carotid artery

Life Sciences

Volumn 80, Issue 19, 2007, Pages 1799-1805

  Tirapelli, Carlos R ^a   Bonaventura, Daniella ^b   de Oliveira, Ana M ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Faculty of Pharmaceutical Sciences   (Brazil)

Author keywords

Bradykinin; Nitric oxide; Prostanoid; Rat carotid; Vasorelaxation

Indexed keywords

7 NITROINDAZOLE; BRADYKININ; BRADYKININ B2 RECEPTOR ANTAGONIST; INDOMETACIN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE INHIBITOR; PHENYLEPHRINE; PROSTAGLANDIN SYNTHASE;

ANIMAL TISSUE; ARTICLE; BLOOD VESSEL REACTIVITY; CAROTID ARTERY; CONTROLLED STUDY; ENDOTHELIUM; ENZYME ACTIVATION; ENZYME ACTIVITY; NONHUMAN; RAT; VASODILATATION;

ANIMALS; BRADYKININ; CAROTID ARTERIES; ENZYME INHIBITORS; HYDRAZINES; IMINES; INDAZOLES; INDOMETHACIN; MALE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; RATS; RATS, WISTAR; RECEPTOR, BRADYKININ B2; VASODILATION; XANTHONES;

RATTUS;

EID: 34047115231     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2007.02.012     Document Type: Article

References (41)

1. Abraham W.M., Scuri M., and Farmer S.G. Peptide and non-peptide bradykinin receptor antagonists: role in allergic airway disease. European Journal of Pharmacology 533 1-3 (2006) 215-221
2. Accorsi-Mendonca D., Correa F.M., Paiva T.B., de Souza H.P., Laurindo F.R., and de Oliveira A.M. The balloon catheter induces an increase in contralateral carotid artery reactivity to angiotensin II and phenylephrine. British Journal of Pharmacology 142 1 (2004) 79-88
3. Akamine E.H., Urakawa T.A., de Oliveira M.A., Nigro D., De Carvalho M.H., Tostes R.C., and Fortes Z.B. Decreased endothelium-dependent vasodilation in diabetic female rats: role of prostanoids. Journal of Vascular Research 43 5 (2006) 403-410
4. Barabe J., Marceau F., Theriault B., Drouin J.N., and Regoli D. Cardiovascular actions of kinins in the rabbit. Canadian Journal of Physiology and Pharmacology 57 1 (1979) 78-91
5. Barrow S.E., Dollery C.T., Heavey D.J., Hickling N.E., Ritter J.M., and Mial J. Effect of vasoactive peptides on prostacyclin synthesis in man. British Journal of Pharmacology 87 (1986) 243-247
6. Birney Y., Redmond E.M., Sitzmann J.V., and Cahill P.A. Eicosanoids in cirrhosis and portal hypertension. Prostaglandins and Other Lipid Mediators 71 1-2 (2003) 3-18
7. Croxatto H., Belmar J., Pereda T., and Labarca E. Hypertensive effects of bradykinin and anephrotensin in normal and nephrectomized animals. Acta Physiology Latino American 12 (1962) 19-21
8. Dabisch P.A., Kerut E.K., Liles J.T., Wien G., Smith M., Patterson M., McCoul E.D., Sears B.W., Saenz R., and Kadowitz P.J. Responses to bradykinin are mediated by NO-independent mechanisms in the rat hindlimb vascular bed. Pharmacology Researchs 50 6 (2004) 575-584
9. Forstermann U., Closs E.I., Pollock J.S., Nakane M., Schwarz P., Gath I., and Kleinert H. Nitric oxide synthase isozymes. Characterization, purification, molecular cloning, and functions. Hypertension 23 6 Pt 2 (1994) 1121-1131
10. Given M.B., Greenberg S.S., and Giles T.D. Coronary vasodilator responses to bradykinin in euglycemic and diabetic rats. Amercan Journal of Hypertension 14 5 Pt 1 (2001) 446-454
11. Gonzalez C., Corbacho A.M., Eiserich J.P., Garcia C., Lopez-Barrera F., Morales-Tlalpan V., Barajas-Espinosa A., Diaz-Munoz M., Rubio R., Lin S.H., Martinez de la Escalera G., and Clapp C. 16K-prolactin inhibits activation of endothelial nitric oxide synthase, intracellular calcium mobilization, and endothelium-dependent vasorelaxation. Endocrinology 145 12 (2004) 5714-5722
12. Gris J.C., Schved J.F., Aguilar-Martinez P., Arnaud A., and Sanchez N. Endothelial mediators regulating vascular tônus. Presse Medicine 20 7 (1991) 303-308
13. Hernanz R., Briones A.M., Alonso M.J., Vila E., and Salaices M. Hypertension alters role of iNOS, COX-2, and oxidative stress in bradykinin relaxation impairment after LPS in rat cerebral arteries. American Journal of Physiology. Heart and Circulatory Physiology 287 1 (2004) H225-H234
14. Honing M.L., Smits P., Morrison P.J., and Rabelink T.J. Bradykinin-induced vasodilation of human forearm resistance vessels is primarily mediated by endothelium-dependent hyperpolarization. Hypertension 35 6 (2000) 1314-1318
15. Johnson A.R. In: Erd6s E. (Ed). Handbook of Experimental Pharmacology vol. 25 (1979), Springer, New York 357-399 Suppl.
16. Kato M., Shiode N., Yamagata T., Matsuura H., and Kajiyama G. Bradykinin induced dilatation of human epicardial and resistance coronary arteries in vivo: effect of inhibition of nitric oxide synthesis. Heart 78 (1997) 493-498
17. Leeb-Lundberg L.M., Marceau F., Muller-Esterl W., Pettibone D.J., and Zuraw B.L. International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacology Reviews 57 (2005) 27-77
18. Maeda Y., Hirano K., Nishimura J., Sasaki T., and Kanaide H. Endothelial dysfunction and altered bradykinin response due to oxidative stress induced by serum deprivation in the bovine cerebral artery. European Journal of Pharmacology 491 1 (2004) 53-60
19. Mccarthy D.A., Potter D.E., and Nicolaides E.D. An in vivo estimation of the potencies and half-lives of synthetic bradykinin and kallidin. Journal of Pharmacology and Experimental Therapeutics 148 (1965) 117-122
20. McLean P.G., Perretti M., and Ahluwalia A. Kinin B1 receptors and the cardiovascular system: regulation of expression and function. Cardiovascular Research 48 (2000) 194-210
21. Mombouli J.V., Illiano S., Nagao T., Scott-Burden T., and Vanhoutte P.M. Potentiation of endothelium-dependent relaxations to bradykinin by angiotensin I converting enzyme inhibitors in canine coronary artery involves both endothelium-derived relaxing and hyperpolarizing factors. Circulation Research 71 (1992) 137-144
22. Nagao T., Illiano S., and Vanhoutte P.M. Heterogeneous distribution of endothelium-dependent relaxations resistant to NG-nitro-l-arginine in rats. American Journal of Physiology 263 (1992) H1090-H1094
23. Nwator I.A., Parsons A.A., and Whalley E.T. Prostanoid involvement in the relaxation of in vitro mesenteric artery by bradykinin and des-Arg9-bradykinin. European Journal of Pharmacology 170 1-2 (1989) 29-33
24. O'Kane K.P.J., Webb D.J., Collier J.G., and Vallance P.J.T. Local l-NG-monomethyl-arginine attenuates the vasodilator action of bradykinin in the human forearm. British Journal of Clinical Pharmacology 38 (1994) 311-315
25. Parratt J.R. A comparison of the effects of the plasma kinins, bradykinin and kallidin, on myocardial blood flow and metabolism. British Journal of Pharmacology and Chemotherapy 22 (1964) 34-46
26. Peredo H.A., Feleder E.C., and Adler-Graschinsky E. Differential effects of acetylcholine and bradykinin on prostanoid release from the rat mesenteric bed: role of endothelium and of nitric oxide. Prostaglandins, Leukotrienes and Essential Fatty Acids 56 4 (1997) 253-258
27. Raidoo D.M., Ramsaroop R., Naidoo S., Muller-Esterl W., and Bhoola K.D. Kinin receptors in human vascular tissue: their role in atheromatous disease. Immunopharmacology 36 2-3 (1997) 153-160
28. Regoli D., and Barabé J. Pharmacology of bradykinin and related kinins. Pharmacology Reviews 32 1 (1980) 1-46
29. Rocha e Silva M., Beraldo W.T., and Rosenfeld G. Bradykinin, a hypotensive and smooth muscle stimulating factor released from plasma globulin by snake venoms and by trypsin. American Journal of Physiology 156 (1949) 261-273
30. Scholkens B.A. Kinins in the cardiovascular system. Immunopharmacology 33 1-3 (1996) 209-216
31. Sharma J.M., and Sharma J. Cardiovascular properties of the kallikrein-kinin system. Current Medical Research and Opinion 18 1 (2002) 10-17
32. Sharma J.N., and Thani R.B. Therapeutic prospects for bradykinin receptor agonists in the treatment of cardiovascular diseases. IDrugs 7 10 (2004) 926-934
33. Starr M.S., and West G.B. The effect of bradykinin and anti-inflammatory agents on isolated arteries. Journal of Pharmacy and Pharmacology 18 12 (1966) 838-840
34. Spillmann F., Van Linthout S., Schulteiss H.P., and Tshope C. Cardioprotective mechanisms of the kallikrein-kinin system in diabetic cardiopathy. Current Opinion in Nephrology and Hypertension 15 1 (2006) 22-29
35. Stewen P., Outi S., Tuulikki N., and Frej F. Cyclic AMP increases bradykinin receptor binding affinity in human endothelial cells. Life Sciences 74 23 (2004) 2839-2852
36. Sturmer E., and Berde B. A comparative pharmacological study of synthetic eledoisin and synthetic bradykinin. Journal of Pharmacology and Experimental Therapeutics 140 (1963) 349-355
37. Tirapelli C.R., De Andrade C.R., Lieberman M., Laurindo F.R., De Souza H.P., and de Oliveira A.M. Vitamin K(1) (phylloquinone) induces vascular endothelial dysfunction: role of oxidative stress. Toxicology and Applied Pharmacology 213 1 (2006) 10-17
38. Toda N. Actions of bradykinin on isolated cerebral and peripheral arteries. American Journal of Physiology 232 3 (1977) H267-H274
39. Wigg S.J., Tare M., Tonta M.A., O'Brien R.C., Meredith I.T., and Parkington H.C. Comparison of effects of diabetes mellitus on an EDHF-dependent and an EDHF-independent artery. American Journal of Physiology. Heart and Circulatory Physiology 281 1 (2001) H232-H240
40. Wimalasundera R., Fexby S., Regan L., Thom S.A., and Hughes A.D. Effect of tumor necrosis factor-alpha and interleukin 1beta on endothelium-dependent relaxation in rat mesenteric resistance arteries in vitro. British Journal of Pharmacology 138 7 (2003) 1285-1294
41. Zhang R.Z., Yang Q., Yim A.P., Huang Y., and He G.W. Different role of nitric oxide and endothelium-derived hyperpolarizing factor in endothelium-dependent hyperpolarization and relaxation in porcine coronary arterial and venous system. Journal of Cardiovascular Pharmacology 43 6 (2004) 839-850